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Abstract
Goals of work Neutropenia is a life-threatening, dose-
limiting toxicity of many chemotherapy regimens. The
goals of this study were to assess the incidence and risk of
chemotherapy-induced neutropenia, febrile neutropenia
(FN) and dose limitations in breast cancer and lymphoma
patients undergoing chemotherapy in Europe.
Patients and methods Four hundred forty-four breast cancer
and 305 lymphoma patients undergoing chemotherapy at 66
practices in five European countries participated in this
prospective, observational study. Predictors of impaired
chemotherapy delivery were investigated using a logistic
regression model.
Main results In breast cancer, FN incidence was low (6%);
however, grade 4 neutropenia was frequent (34%). Lymphoma
patients experienced higher incidences of FN (non-Hodgkin
lymphoma (NHL) 22%; Hodgkin lymphoma (HL) 15%) and
grade 4 neutropenia (NHL 54%; HL 40%). For both diseases,
FN and grade 4 neutropenia were associated with low relative
dose intensity (RDI). Multivariate regression models indicated
that first cycle FN, age≥65 years and Eastern Co-operative
Oncology Group>1 were associated with low RDI in breast
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cancer and lymphoma, while colony-stimulating factor (CSF)
primary prophylaxis appeared to be protective in lymphoma
only. Primary CSF prophylaxis was provided to 9% of breast
cancer, 28% of NHL and 19% of HL patients.
Conclusions Neutropenia and low RDI remain serious
problems in both breast cancer and lymphoma populations
undergoing chemotherapy. Several risk factors which can
trigger reduced chemotherapy delivery were identified.
These results can support physicians in identifying patients
most at risk of receiving impaired chemotherapy delivery
who would benefit from suitable preventive measures.
Keywords Breast cancer . Lymphoma . Neutropenia .
Risk model . Relative dose intensity
Introduction
Myelosuppression represents the major dose-limiting tox-
icity of anti-cancer chemotherapy [10]. Chemotherapy-
induced neutropenia (CIN) can lead to febrile neutropenia
(FN), which requires immediate hospitalisation and treat-
ment with antibiotics for patients with increased risk of life-
threatening infections [8, 10, 24]. The level of in-hospital
mortality associated with patients who are hospitalised for
FN is 9.5% on average and more than 21% for patients with
co-morbidities [12].
Chemotherapy dose reductions and dose delays, as a
result of CIN and FN, can lead to reduced patient survival
[2–5, 13–15, 17]. The risk of CIN and FN is particularly
high for elderly patients [1, 29, 33], which may account for
a tendency to reduce chemotherapy treatment in this group
[1, 15, 29].
Despite the potential consequences of myelosuppression,
myelotoxic chemotherapy remains central to the current
standard of care for breast cancer and lymphoma patients.
Over the past decade, breast cancer chemotherapy regimens
based on cyclophosphamide, methotrexate and fluorouracil
(CMF) have been superseded by more efficacious, but still
myelotoxic, anthracycline-based regimens, such as fluoro-
uracil, epirubicin and cyclophosphamide (FEC) [1, 30, 34].
Increased myelotoxicity might occur due to the adoption of
some taxane-based therapies, such as docetaxel, doxorubi-
cin and cyclophosphamide (TAC) [1, 20], which was
recently recommended in treatment guidelines for early
node-positive breast cancer [23].
For patients with aggressive non-Hodgkin lymphoma
(NHL), combination therapy with cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) has been
the standard treatment since its development in the 1970s
[31]. The recent addition of rituximab to the regimen has
further improved patient outcomes [6, 31], although both
regimens carry a significant risk of neutropenia [1, 19,
33]. Dose-dense CHOP (CHOP-14; administered every
14 days, supported with colony-stimulating factor) has
been shown to improve patient survival compared with the
21-day regimen in both young and old patients [26, 27].
The most commonly used chemotherapy regimens for
patients with Hodgkin lymphoma (HL) are associated with
a lower risk of neutropenia; doxorubicin, bleomycin,
vinblastine and dacarbazine (ABVD) or Stanford V (mech-
lorethamine, doxorubicin, etoposide, vincristine, vinblastine,
bleomycin and prednisone) are widely used for early-stage
disease, whilst bleomycin, etoposide, doxorubicin, cyclo-
phosphamide, vincristine, procarbazine and prednisone
(BEACOPP) is an additional option for advanced-stage
disease [11, 21].
Primary prophylaxis with colony-stimulating factors
(CSFs) reduces the risk of FN [1, 7, 22, 33] and related
chemotherapy dose reductions [25]. Therefore, a major
treatment goal is to identify patients most at risk of
developing neutropenia and its consequences before they
begin their chemotherapy treatment [18].
The Impact of Neutropenia in Chemotherapy—European
(INC-EU) Study Group has pioneered this work within
Europe, with the recent publication of a multi-national
retrospective study addressing the incidence and risk factors
of dose delays, dose reductions and hospitalisations related
to neutropenia induced by adjuvant breast cancer chemo-
therapy [30]. Parallel retrospective studies in the US have
resulted in similar advances for breast cancer and lympho-
ma patients [15, 17]. Although these studies are clearly
informative, retrospective data are limited by centre-
specific deficits and differences in data availability.
The present paper presents results from a prospective
study; the INC-EU Prospective Observational European
Neutropenia Study was conducted to assess the incidence
and predictors of grade 3–4 neutropenia, FN and reduced
chemotherapy administration for breast cancer and lym-
phoma patients undergoing chemotherapy in European
community practices. This paper reports the incidences of
CIN, FN and related hospitalisations in these patient
groups, as well as patterns of CSF use and chemotherapy
dose limitations. A logistic regression analysis of impaired
chemotherapy delivery is also presented. Work on regres-
sion models of FN occurrence is ongoing.
Patients and methods
Study design and patient selection
This prospective study was conducted in 66 centres in
Belgium, France, Germany, Spain and the UK. Ethical
approval was obtained for all centres and all participants
provided their informed consent. The design was observa-
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tional, and treatment was as per normal institutional clinical
practice with the exception of a complete blood count at the
expected (protocol defined) absolute neutrophil count
(ANC) nadir in cycle 1. Centres were required to record
all blood counts taken during each patient’s chemotherapy
treatment.
Patients with a histologically confirmed diagnosis of
malignancy were eligible for inclusion: Breast cancer
patients requiring adjuvant or neo-adjuvant chemotherapy
were accrued from the full range of stages I to III, fitting the
primary tumour, nodes and metastasis classification of T 0–
3, N 0–2, M 0. Stage 4 breast cancer patients were not
included because these patients are often treated with less
aggressive regimens with the intent of prolonging or
improving quality of life, rather than cure. Lymphoma
patients with HL stage IB–IV or with NHL with an
International Prognostic Index of 0–3 needing chemother-
apy were also eligible. Adult participants (age 18 or older,
without upper age limit) had to start a new myelosuppres-
sive chemotherapy regimen sequence with at least four
cycles planned. Prior or concurrent radiation therapy was
allowed.
Key exclusion criteria were: active infection within 72 h
prior to start of chemotherapy, conditions causing neutrope-
nia, malignant conditions with myeloid characteristics, use
of antibody-based or cell-based immunotherapies (with the
exception of rituximab), history of stem cell or bone marrow
transplantation and concurrent participation in phase I or
phase II trials. Concomitant treatments deemed necessary to
provide adequate supportive care were permitted. Patients
were observed until the end of their chemotherapy regimen.
Non-completion of planned chemotherapy regimens did not
lead to exclusion from the study.
The primary endpoint was the incidence of grade 3
(ANC<1.0×109/L) and grade 4 neutropenia (ANC<0.5×
109/L). Secondary endpoints included incidence of: FN
(grade 4 neutropenia and temperature≥38°C), chemothera-
py cycle delays or dose reductions, relative dose intensity
(RDI), neutropenia-related hospitalisations and patterns of
CSF use.
Dose reductions were defined as a reduction of ≥10% of
planned dose of at least one drug in at least one cycle; dose
delays were defined as a delay of ≥4 days in at least one
cycle. RDI was defined as the ratio of the drug dose
Table 1 Patient and disease characteristics of breast cancer and lymphoma patients
Characteristic Breast cancer (N=444) NHL (N=240) HL (N=65)
Age, years; mean±SD (range) 53.5±10.2 (27–81) 63.2±12.9 (17–90) 39.2±17.5 (18–79)
Female gender, n (%) 444 (100) 105 (43.8) 28 (43.1)
Oestrogen receptor status positive, n (%) 297 (67.4a) – –




Disease stage at inclusion, n (%) I 109 (24.9c) – –
II 241 (55.0c)
III 88 (20.1c)
Ann Arbor staging, n (%) I – 42 (17.7d) 6 (9.2)
II 62 (26.2d) 34 (52.3)
III 39 (16.5d) 12 (18.5)
IV 94 (39.7d) 13 (20.0)
B symptoms, n (%) – 113 (47.7d) 36 (55.4)
IPI index, n (%) low (0–1) – 75 (31.7d) –
intermediate (2–3) 132 (55.7d)
high (≥4) 30 (12.7d)
No. of co-morbidities (mean±SD, range) 1.6±2.1 2.1±2.1 0.9±1.3
0–11 0–11 0–6
Cardiovascular co-morbidity, n (%) 95 (21.4) 65 (27.1) 8 (12.3)
Renal co-morbidity, n (%) 13 (2.9) 16 (6.7) 1 (1.5)
NHL Non-Hodgkin lymphoma, HL Hodgkin lymphoma, HER2 human epidermal growth factor receptor 2, IPI International Prognostic Index
a n=441 due to missing values
b n=375 due to missing values
c n=438 due to missing values
d n=237 due to missing values
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actually administered in the actual time, over the planned
dose in the planned time. Drug-specific RDIs obtained for
each anti-malignant drug were averaged across each
component of the chemotherapy regimen and across all
planned chemotherapy cycles, regardless of whether they
were administered or not. Corticosteroids and immunother-
apeutic agents, including rituximab, were disregarded for
RDI calculations. Low RDI was defined as RDI≤85%.
Hospitalisations were classified as neutropenia-related or
not. CSF use was defined as primary prophylaxis (CSF use
in the first cycle before a documented grade 3–4 CIN
occurred or denoted as primary prophylaxis by site) or other
use (incorporating CSF prophylaxis in cycles other than the
first and CSF use in treatment).
Statistical methods
Assuming a dropout rate of 10%, 450 breast cancer patients
and 300 lymphoma patients were required to allow accurate
estimation of the incidence of grade 3–4 CIN, with a 95%
confidence interval (CI) width of ±6% for each patient
group (assuming an incidence rate of 20–30% for breast
cancer and 40–60% for lymphoma patients) and for
detecting relationships between various covariates and the
incidence of neutropenia with 90% statistical power
(assuming an underlying odds ratio of 2.25). Data were
summarised using descriptive statistics. Preparatory univar-
iate testing and subsequent multivariate logistic regression,
using generalised-estimation-equations-based robust stan-
dard errors to allow for clustering by study centre, were
used to assess predictors of low RDI, separately for breast
cancer and lymphoma patients.
Covariates assessed for their relationship with low RDI
included demographic information, patient and disease
characteristics, co-morbidities (number and type), baseline
laboratory data (including blood counts and constituent
biochemical data), planned and actual treatment character-
istics and neutropenic events. Assumed direct correlates of
RDI were not used as covariates.
All tests were two-sided at the 5% significance level.
Two-sided 95% CIs are shown, except where otherwise
stated. CI calculation for binary variables assumed a
binomial distribution. Statistical analyses were performed
using the STATA® version 9 statistical package.
Results
Patient characteristics
A total of 759 patients were enrolled between January 2004
and May 2005, of whom ten were not evaluable due to
Table 2 Treatment characteristics for breast cancer patients








Total 444 100 9.3d (41) 24.4d (108)
Anthracycline
based
312 70.3 4.5d (14) 23.2d (72)
AC 74 16.7 1.4d (1) 5.5d (4)
EC 38 8.6 10.5 (4) 31.6 (12)
FAC 11 2.5 0 (0) 0 (0)
FEC 152 34.2 6d (9) 31.1d (47)
E-CMF 34 7.7 0 (0) 23.5 (8)












87 19.6 12.6 (11) 33.3 (29)





8 1.8 25.0 (2) 50.0 (4)
Taxane-based 2 0.5 0 (0) 0 (0)
CMF 18 4.1 11.1 (2) 5.6 (1)
CSF Colony-stimulating factor, AC adriamycin (doxorubicin) and
cyclophosphamide, EC epirubicin and cyclophosphamide, FAC 5-
fluorouracil, adriamycin (doxorubicin) and cyclophosphamide, FEC
5-fluorouracil, epirubicin and cyclophosphamide, E-CMF epirubicin,
cyclophosphamide, methotrexate and 5-fluorouracil; TAC taxotere
(docetaxel), adriamycin (doxorubicin) and cyclophosphamide; CMF
cyclophosphamide, methotrexate and 5-fluorouracil
a Cycle length was 3 weeks for the majority of cases. AC: mostly
doxorubicin 60 mg/m2 ; cyclophosphamide 600 mg/m2 . EC: mostly
epirubicin 90 mg/m2 ; cyclophosphamide 600 mg/m2 . FEC: mostly 5-
fluorouracil 500–600mg/m2 ; epirubicin 100 mg/m2 ; cyclophosphamide
500–600 mg/m2 ; cycle length of 4 weeks with drug administrations
on cycle days 1 and 8 used in 11 cases. E-CMF: mostly epirubicin
100 mg/m2 followed by classical four weekly CMF, oral or iv-
based. Sequential regimens composed of an anthracycline-based
regimen and a taxane: first part mostly AC, EC or FEC; second part
mostly docetaxel 100 mg/m2 or paclitaxel 175 mg/m2 . TAC:
docetaxel 75 mg/m2 ; doxorubicin 50 mg/m2 ; cyclophosphamide
500 mg/m2 . CMF: classical four weekly CMF, oral or iv-based.
b Other colony-stimulating factor (CSF) use: secondary prophylaxis or
treatment.
c Denominator values for calculations are the regimen n-values in
column 2, except where indicated.
d Denominator n-value=442 (total) and 310 (anthracycline based); 73
(AC); 151 (FEC) due to missing values.
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Table 3 Treatment characteristics for lymphoma patients
Regimen group Number Distribution (%) Primary CSF
prophylaxis %c (n)
Other CSF




Total 240 100 27.5 (66) 28.8 (69) 81.7 (196)
CHOP-21-likeb 178 74.2 12.4 (22) 34.3 (61) 86.5 (154)
CHOP-14-like 41 17.1 75.6 (31) 9.8 (4) 65.9 (27)
ACVBP like 9 3.8 55.6 (5) 33.3 (3) 77.8 (7)
NHL other 12 5.0 66.7 (8) 8.3 (1) 66.7 (8)
HL
Total 65 100 18.5 (12) 36.9 (24) –
ABVD like 47 72.3 8.5 (4) 44.7 (21) –
Hodgkin other 18 27.7 44.4 (8) 16.7 (3) –
Stanford V 5 7.7 20.0 (1) 0 (0) –
BEACOPP-like 8 12.3 62.5 (5) 25.0 (2) –
ChlVPP-like 5 7.7 40.0 (2) 20.0 (1) –
CSF Colony-stimulating factor, CHOP cyclophosphamide, hydroxydaunomycin (doxorubicin), oncovin (vincristine) and prednisone, ACVBP
adriamycin (doxorubicin), cyclophosphamide, vindesine, bleomycin and prednisone, NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma,
ABVD adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine, BEACOPP bleomycin, etoposide, adriamycin (doxorubicin),
cyclophosphamide, oncovin (vincristine), procarbazine and prednisone, ChlVPP chlorambucil, vinblastine, procarbazine and prednisone
a Other CSF use, non-primary prophylaxis or treatment.
b Includes six patients with a cycle length of 28 days.
c Denominator values for percentage calculations are the regimen n-values in column 2.
Table 4 Occurrence of neutropenia and FN by regimen for breast cancer and lymphoma patients




First cycle grade 4
neutropenia %a (95% CI)
First cycle FN %a
(95% CI)
Breast cancer
Total 444 34.4 (30.0–39.0)b 5.9 (3.9–8.5)b 24.4 (20.5–28.7)b 3.9 (2.3–6.1)b
Anthracycline based 312 36.7 (31.3–42.3)c 6.4 (4.0–9.8)c 28.5 (23.5–33.9)c 4.2 (2.3–7.1)c
Anthracycline and taxane
containing excluding TAC
95 31.6 (22.4–41.9) 5.3 (1.7–11.9) 17.2 (10.2–26.4)d 3.2 (0.7–9.0)
TAC 17 43.8 (19.8–70.1)e 5.9 (0.1–28.7) 18.8 (4.0–45.6)e 5.9 (0.1–28.7)
CMF 18 5.6 (0.1–27.3) 0.0 (0.0–18.5)g 0.0 (0.0–18.5)f,g 0.0 (0.0–19.5)f,g
NHL
Total 240 53.8 (47.2–60.2) 22.1 (17.0–27.9) 34.6 (28.6–41.0) 8.9 (5.5–13.1)
CHOP-21 like 178 53.4 (45.8–60.9) 21.9 (16.1–28.7) 34.8 (27.9–42.3) 9.6 (5.7–14.9)
CHOP-14 like 41 48.8 (32.9–64.9) 17.1 (7.2–32.1) 24.4 (12.4–40.3) 2.4 (0.1–12.9)
ACVBP like 9 88.9 (51.8–99.7) 44.4 (13.7–78.8) 77.8 (40.0–97.2) 0.0 (0.0–33.6)g
NHL other 12 50.0 (21.1–78.9) 25.0 (5.5–57.2) 33.3 (9.9–65.1) 25.0 (5.5–57.2)d
HL
Total 65 40.0 (28.0–52.9) 15.4 (7.6–26.5) 24.6 (14.8–36.9) 6.2 (1.7–15.0)
ABVD like 47 34.0 (20.9–49.3) 14.9 (6.2–28.3) 21.3 (10.7–35.7) 8.5 (2.4–20.4)
HL other 18 55.6 (30.8–78.5) 16.7 (3.6–41.4) 33.3 (13.3–59.0) 0.0 (0.0–18.5)d
FN Febrile neutropenia, TAC taxotere (docetaxel), adriamycin (doxorubicin) and cyclophosphamide, CMF cyclophosphamide, methotrexate and
5-fluorouracil, NHL non-Hodgkin lymphoma, CHOP cyclophosphamide, hydroxydaunomycin (doxorubicin), oncovin (vincristine) and
prednisone, ACVBP adriamycin (doxorubicin), cyclophosphamide, vindesine, bleomycin and prednisone, HL Hodgkin lymphoma, ABVD
adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine; CIN chemotherapy-induced neutropenia
a Denominator values are regimen n-values except where indicated.
b Denominator n-value=442 (any grade IV CIN); 441 (any FN, cycle 1 FN); 438 (cycle 1 grade IV CIN) due to missing values.
c Denominator n-value=311 (any grade IV CIN); 310 (any FN, cycle 1 FN); 309 (cycle 1 grade IV CIN) due to missing values.
d Denominator n-value=93 due to missing values.
e Denominator n-value=16 due to a missing value.
f Denominator n-value=17 due to a missing value.
g One-sided 97.5% CI.
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almost complete lack of data. Eight of these ten patients
were found to be ineligible. The distribution of the
remaining 749 patients was: Belgium, 105 (14%); France,
94 (13%); Germany, 306 (41%); Spain, 38 (5%); and UK,
206 (28%). Patient split by diagnosis was; breast cancer
444 (59%); NHL 240 (32%); HL 65 (9%). Four NHL
patients were classified as relapsed leukaemias. Patient and
disease characteristics are summarised in Table 1.
Treatment characteristics
Over 70% of breast cancer patients received anthracycline-
based regimens, with FEC being the most frequent regimen
(34%), followed by anthracycline–taxane regimens (25%;
Table 2). Non-anthracycline, taxane-based and CMF regi-
mens were used infrequently. The planned number of
chemotherapy cycles (mean±SD) was 5.5±1.1 in those
receiving non-sequential regimens and 7.9±0.8 in those
receiving sequential regimens. Cycle length was usually
3 weeks. Primary prophylaxis with CSFs was generally low
at 9%, although more than 70% of patients receiving TAC
also received primary CSF prophylaxis (Table 2).
CHOP-21 and CHOP-14 regimens were used in 74%
and 17% of NHL patients, respectively (Table 3). Ritux-
imab use was high, averaging 82% across all NHL
regimens. The planned number of chemotherapy cycles
(mean±SD) was 6.2±1.5 and cycle length was usually
3 weeks. Twelve per cent of patients receiving CHOP-21
regimens and 76% of patients on the dose-dense CHOP-14
regimens received prophylactic CSF support from the first
cycle (Table 3).
The majority of HL patients received ABVD-like
regimens (72%), with BEACOPP being the second most
common category (12%; Table 3). The planned number of
chemotherapy cycles (mean±SD) was 5.4±1.7 and cycle
length was usually 4 weeks. Primary prophylactic CSF use
for HL patients averaged at 19%, ranging from 9% for
ABVD-like regimens to 63% for BEACOPP-like regimens.
Incidence of neutropenia and FN
Table 4 details the incidence of neutropenia and FN across
all cycles of chemotherapy and during the first cycle. Grade
3–4 neutropenia occurred in 64% of breast cancer patients,
with 34% experiencing grade 4 CIN; in contrast, FN
occurred in only 6% of breast cancer patients. The
incidence of grade 3–4 neutropenia was 72% for NHL
patients (54% experienced grade 4) and 75% for HL
Table 5 Occurrence of chemotherapy dose limitations in breast cancer and lymphoma patients
Regimen group N Dose delay ≥ 4 daysa %d
(95% CI)
Dose reduction ≥ 10%b %d
(95% CI)
RDI ≤ 85%c %d
(95% CI)
Breast cancer
Total 444 35.1 (30.7–39.8) 14.2 (11.1–17.8) 21.4 (17.7–25.5)
Anthracycline based 312 36.5 (31.2–42.1) 12.2 (8.8–16.3) 22.4 (17.9–27.5)
Anthracycline- and taxane
containing excluding TAC
95 32.6 (23.4–43.0) 20.0 (12.5–29.5) 16.8 (9.9–25.9)
TAC 17 29.4 (10.3–56.0) 17.6 (3.8–43.4) 29.4 (10.3–56.0)
CMF 18 22.2 (6.4–47.6) 11.1 (1.4–34.7) 11.1 (1.4–34.7)
NHL
Total 240 45.8 (39.4–52.4) 33.3 (27.4–39.7) 36.3 (30.2–42.7)
CHOP-like three weekly 178 46.1 (38.6–53.7) 35.4 (28.4–42.9) 33.2 (26.3–40.6)
CHOP-like two weekly 41 46.3 (30.7–62.6) 24.4 (12.4–40.3) 43.9 (28.5–60.3)
ACVBP like 9 44.4 (13.7–78.8) 44.4 (13.7–78.8) 55.6 (21.2–86.3)
NHL other 12 41.7 (15.2–72.3) 25.0 (5.5–57.2) 41.7 (15.2–72.3)
HL
Total 65 60.0 (47.1–72.0) 46.2 (33.7–59.0) 32.3 (21.2–45.1)
ABVD like 47 66.0 (50.7–79.1) 36.2 (22.7–51.5) 29.8 (17.3–44.9)
Other 18 44.4 (21.5–69.2) 72.2 (46.5–90.3) 38.9 (17.3–64.3)
CI Confidence interval, RDI relative dose intensity; TAC taxotere (docetaxel), adriamycin (doxorubicin) and cyclophosphamide; CMF
cyclophosphamide, methotrexate and 5-fluorouracil, NHL non-Hodgkin lymphoma, CHOP cyclophosphamide, hydroxydaunomycin (doxorubi-
cin), oncovin (vincristine) and prednisone; ACVBP adriamycin (doxorubicin), cyclophosphamide, vindesine, bleomycin and prednisone; HL
Hodgkin lymphoma; ABVD adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine
a In at least one cycle.
b In at least one anti-malignant drug and at least one cycle.
c RDI was corrected for planned but non-administered cycles.
d Denominator values are regimen n-values.
1304 Support Care Cancer (2008) 16:1299–1309
patients (40% experienced grade 4). FN occurred in 22% of
patients with NHL and 15% of HL patients. For both breast
cancer and lymphoma patients, a high proportion of
neutropenic events occurred during the first cycle of
chemotherapy. Neutropenia-related hospitalisations oc-
curred in 18% of NHL patients, 14% of HL patients and
5% of breast cancer patients.
Chemotherapy dose limitations
Eighty-six per cent of breast cancer patients received their
planned number of chemotherapy cycles. More than one in
five patients experienced some form of dose limitation.
Dose delays≥4 days occurred in 35% of patients, dose
reductions of ≥10% occurred in 14% of patients and 21% of
the breast cancer patients received RDI≤85% (Table 5). For
lymphoma, 72% of NHL patients completed their planned
treatment cycles; dose delays occurred in 46% of patients,
dose reductions in 33% of patients and 36% of NHL
patients received RDI≤85%. In HL patients, 85% of whom
completed their planned treatment cycles, dose delays
occurred in 60% of patients, dose reductions in 46% and
RDI≤85% occurred in 32% of patients (Table 5).
Predictors of impaired chemotherapy delivery
The occurrence of CIN and FN had an impact on
chemotherapy delivery. Figure 1 shows the results of a
univariate analysis of the effects of grade 4 neutropenia and
FN on the proportion of breast cancer and NHL patients
experiencing dose delays, dose reductions and low RDI.
Both groups were more likely to experience a dose delay if
they also experienced grade 4 neutropenia, compared to
patients with no neutropenic events (p<0.05 and p<0.01,
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Fig. 1 Chemotherapy dose delays and reductions by neutropenic
event. Data are shown for breast cancer patients (a) and NHL patients
(b). Data represent univariate analyses and are not adjusted for
confounding factors. Error bars represent 95% CIs. * p<0.05, ** p<
0.01, *** p<0.001, when compared to patients with no events
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and low RDI were more common in patients who
experienced either grade 4 neutropenia or FN (p<0.001
and p<0.01, for dose reductions and RDI≤85%, respec-
tively). Overall, 28% of breast cancer patients and 36% of
NHL patients who experienced grade 4 neutropenia
received RDI≤85%. For breast cancer and NHL patients
who experienced FN, RDI≤85% occurred in 42% and 45%,
respectively.
Multivariate logistic regression analysis identified three
covariates that were significantly associated with low RDI
occurrence in the breast cancer as well as lymphoma
populations and showed similar effect sizes: ECOG status>
1, age≥65 years and cycle 1 FN occurrence (Table 6).
When grade 4 neutropenia occurrence in cycle 1 was used
as an alternative predictor to the cycle 1 FN covariate, the
resulting odds ratios were 1.94 (CI 1.22–3.07; p=0.005) in
breast cancer and 1.37 (CI 0.80–2.35; p=0.258) in
lymphoma. Primary CSF prophylaxis had a strong protec-
tive effect for lymphoma. No such association was
observed for breast cancer; however, it is important to
consider this result in the context of the FN risk for each
disease entity and factors driving provision of CSF (Table 4;
see “Discussion”). Type of chemotherapy regimen was also
significantly associated with low RDI occurrence in
lymphoma.
Discussion
This study assessed the incidences of CIN and FN and their
consequences for chemotherapy delivery in breast cancer
and lymphoma patients undergoing chemotherapy in
European academic and community practices between
2004 and 2006.
A significant proportion of FN and grade 4 neutropenia
occurred in the first cycle of chemotherapy for the majority
of regimens considered. This finding is consistent with
reports from other studies [9, 16, 28].
The incidence of FN for the most frequently used breast
cancer regimens in European practice was low (6%).
However, grade 4 neutropenia occurred in a high proportion
of patients (34%) and significantly impacted upon chemo-
therapy delivery. Over 20% of breast cancer patients
received RDI≤85%, which has been shown to impact on
survival [5].
Over 20% of NHL patients and 15% of HL patients
developed FN at some point during the course of their
chemotherapy treatment. Many lymphoma patients (54% of
NHL and 40% of HL patients) also experienced grade 4
neutropenia, which was associated with delays in planned
chemotherapy treatment. Dose reductions were also fre-
quent in this patient group; overall, 30% of lymphoma
patients received RDI≤85%. Recent results show that even
reducing RDI to less than 90% can impact on survival in
NHL patients receiving CHOP-21 [3].
A certain underestimation of neutropenia rates and, to a
lesser extent, FN rates may have occurred because the
frequency of blood counts was according to local institu-
tional practice (apart from the protocol-specified blood
count taken at cycle 1 nadir). However, the observed FN
rates were generally in the range expected by current
European Organisation for Research and Treatment of
Cancer and American Society of Clinical Oncology guide-
lines [1, 33]. The FN risk of patients treated with
anthracycline-based regimens was <10%. Regimens with
concomitant anthracyclines and taxanes that have a high
(> 20%) generic FN risk, such as TAC, were appropriately
supported by primary CSF prophylaxis in most cases.
CHOP-21-like regimens were expected to have an interme-
diate to high risk of FN (17–50%) [1]. In the present study,
the overall FN rate for patients receiving CHOP-21-like
regimens was 22% and primary CSF prophylaxis was
provided to only 12% of these patients. This examination of
the level of prophylactic CSF support provided to lympho-
ma patients, who frequently experienced CIN and FN,
indicates that a shift in practice would be required if current
European guidelines are to be followed [1].
Table 6 Multivariate models of low RDI occurrence





Age≥65 years 1.73 (1.12–2.70), 0.014 1.74 (1.12–2.70), 0.013
ECOG>1 4.13 (1.39–12.22), 0.010 2.42 (1.25–4.70), 0.009
Cycle 1 FN 3.68 (1.55–8.73), 0.003 2.27 (0.94–5.51), 0.069
Primary CSF
prophylaxis
Ns 0.46 (0.23–0.93), 0.029
Regimen Ns
CHOP-14-likec 2.12 (0.85–5.27), 0.106
ACVBP likec 5.51 (2.27–13.39), <0.001
NHL otherc 2.17 (0.58–8.06), 0.247
ABVD likec 1.12 (0.59–2.13), 0.719
Hodgkin otherc 2.15 (0.86–5.33), 0.100
RDI Relative dose intensity, OR odds ratio, CI confidence interval,
ECOG Eastern Co-operative Oncology Group, FN febrile neutropenia,
CSF colony-stimulating factor, ns non-significant, CHOP cyclophos-
phamide, hydroxydaunomycin (doxorubicin), oncovin (vincristine)
and prednisone; ACVBP adriamycin (doxorubicin), cyclophospha-
mide, vindesine, bleomycin and prednisone; NHL non-Hodgkin
lymphoma; ABVD adriamycin (doxorubicin), bleomycin, vinblastine
and dacarbazine
aN=437 due to missing values. Pseudo R2 =0.027. Robust standard
error estimates adjusted for 39 clusters (centres).
bN=304 due to missing values. Pseudo R2 =0.056. Robust standard
error estimates adjusted for 39 clusters (centres).
c Reference: CHOP-21-like chemotherapy. p=0.008 (Wald test based)
for this set of parametres.
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The practice of responding to FN by delaying or
reducing chemotherapy has potentially serious consequen-
ces for patients including reduced survival [2, 3, 5].
Therefore, clinicians need to be made aware of the factors
that can trigger chemotherapy dose limitations. We have
modelled the factors associated with low RDI and shown
that age≥65 years, ECOG>1 and cycle 1 FN are specific
risk factors for low RDI in breast cancer as well as
lymphoma populations. Our results are consistent with
other risk models, as recently reviewed by Lyman et al.
[18]. Age≥65 years has been identified as a risk factor for
low RDI in both breast cancer [15, 19, 32] and NHL
patients [17, 19]. Poor performance status has been
identified as a risk factor for low RDI in patients with
NHL [17] and the present results extend this finding to
patients with breast cancer. We also specifically identified
cycle 1 FN and cycle 1 grade 4 neutropenia as risk factors
for low RDI, complementing the results of other studies
[32]. The effect of these latter factors was stronger in the
breast cancer population than in lymphoma where neutro-
penic events are more frequent and may be managed with
greater routine. Further external validation of these findings
is of importance.
Interestingly, in the regression models, a protective effect
of primary CSF prophylaxis against low RDI was observed
for lymphoma but not for breast cancer patients. This
finding was unexpected and the most likely explanation is
that most breast cancer patients received chemotherapy
regimens with low FN risk, and primary CSF prophylaxis
was only provided to those few patients who received high-
risk regimens or was targeted to patients who did not
require it. This selective use of CSF prophylaxis could not
be represented in the model.
Choice of chemotherapy regimen is a key driver of
adverse events including neutropenia and FN and therefore
contributes to every patient’s risk of low RDI. In this
analysis, regimen type was a significant covariate in the
lymphoma model but not in the breast cancer model. It
appears that the breast cancer regimen types considered in
this study had a similar potential to trigger low RDI, after
modification by other factors (such as whether CSF
prophylaxis was provided or not). In lymphoma, the set of
covariates representing regimen types was statistically
significant in its entirety and needed to be included in the
model to avoid residual confounding. However, the
individual coefficients were mostly non-significant and
should be interpreted with great care.
The overall predictive ability of the low RDI models
remained low, which is partially explained by a special
characteristic. The factors identified here and in other
published models of low RDI occurrence do not cause
low RDI directly, they only influence clinical decision
making, which is subject to substantial variation. Ulti-
mately, low RDI is always a direct consequence of clinical
decisions to dose delay or dose reduce (which are based on
personal judgment and/or local institutional practice).
Therefore, it would be difficult, and perhaps problematic,
to construct clinical prediction rules for low RDI (while
constructing prediction rules for other endpoints such as FN
makes perfect sense). The contribution of low RDI models
is to make clinicians aware of factors that often trigger
decisions towards impaired chemotherapy delivery and
thus, perhaps, to change clinical behaviours and improve
patient management at both individual and institutional
levels.
In sum, this prospective observational study provides
information about the occurrence of CIN and FN in current
European community practice and examines how neutro-
penic events and other factors impact upon chemotherapy
delivery. The results indicate that neutropenia and impaired
chemotherapy delivery remain serious problems in both
breast cancer and lymphoma patient populations. Rather
than acting to prevent, current clinical practice frequently
delays or reduces chemotherapy, which may have severe
long-term implications [2, 3, 5].
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